



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

4th June 2024

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sir,

Re: Submission of our AGM Notice & Annual Report (Directors' Report & the Accounts)

Pursuant to clause 34 of the Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, we are submitting the Business Responsibility and Sustainability Report for Financial Year (FY) 2023- 24, which also forms part of the Annual Report.

Kindly take submission on record.

Thanking you,

Yours faithfully

For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



Business Responsibility and Sustainability Report

GlaxoSmithKline Pharmaceuticals Limited

FY 2023-24

About this report

The contents of this report are aligned with the 9 principles contained in the National Guidelines on Responsible Business Conduct (NGRBC) charted out by the Ministry of Corporate Affairs on Environmental, Social and Governance parameters for Financial Year ('FY') 2023-24.

The report complies with the requirements for disclosing sustainability-related information aligned to the 9 principles of the NGRBC. Our disclosures around the non-financial performance indicators also seeks to enhance connectivity within your company's general purpose financial reporting and the management of sustainability related impacts within our own operations.

Table of Contents

Section A: General Disclosures	4
Section B: Management and Process Disclosures	10
Section C: Principle-wise Performance Disclosure	13
Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.	13
Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe	16
Principle 3: Businesses should respect and promote the well-being of all employees, including those in their value chains	18
Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders	25
Principle 5: Businesses should respect and promote human rights	28
Principle 6: Businesses should respect and make efforts to protect and restore the environment	31
Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent	37
Principle 8: Businesses should promote inclusive growth and equitable development	38
Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner	40

Section A: General Disclosures

Details of the Listed Entity

1.	Corporate Identity Number (CIN) of your company	L24239MH1924PLC001151
2.	Name of your company	GlaxoSmithKline Pharmaceuticals Limited ('GSK' or 'your company' or 'we')
3.	Year of incorporation	1924
4.	Registered office address	GlaxoSmithKline Pharmaceuticals Limited, GSK House, Worli, Dr Annie Besant Road, Mumbai- 400030
5.	Corporate address	Same as above
6.	E-mail	in.investorquery@gsk.com
7.	Telephone	+91 22 24959595
8.	Website	https://india-pharma.gsk.com/en-in/
9.	Financial year for which reporting is being done	FY 2023-24
10.	Name of the stock exchange(s) where shares are listed	BSE Ltd. (Bombay Stock Exchange) and the National Stock Exchange of India Ltd. (NSE).
11.	Paid-up capital	INR 16,940.60 Lakhs
12.	Name and contact details (telephone, email address) of the person who may be contacted in case of any queries on the Business Responsibility and Sustainability Report	Name: Mr. Ajay Nadkarni Designation: Company Secretary Telephone no.: +91 22 2495 9595 Email ID: in.investorquery@gsk.com
13.	Reporting boundary	Standalone basis
14.	Name of assurance provided	Bureau Veritas
15.	Type of assurance obtained	Reasonable Assurance

Products/Services

1. Details of business activities (accounting for 90% of the turnover):

Your company is engaged *inter alia*, in the business of manufacturing, distributing, and trading in pharmaceuticals.

2. Products/Services sold by the entity (accounting for 90% of the entity's Turnover):

Sr. No.	Product/Service	NIC Code	% of total Turnover Contributed
1.	Pharmaceuticals	21002	100%

3. Number of locations where plants and/or operations/offices of the entity are situated:

Number of Plants	Number of Offices
One Manufacturing plant at Nashik	One head office at Mumbai
	Five branches in India

Markets Served by the Entity

1. **Locations** - Across all markets in India

2. **Exports** - Your company does not export its products.

3. **Customers** - Customers are important stakeholders in our business. Our company's customer base includes Stockists, Health Care Professionals ('HCPs'), Hospitals and Government Institutions to whom your company sells its products.

Employees

Details as on end of Financial Year of Total Workforce:

Particulars	Total	Male	Male %	Female	Female %
Permanent Employees	1575	1324	84%	251	16%
Permanent Workers ¹	1636	1451	89%	185	11%

Differently Abled Employees:

Particulars	Total	Male	Female
Permanent Employees	0	0	0
Permanent Workers	0	0	0

Participation/Inclusion/Representation of Women:

Particulars	Total	Number	Percentage
Board of Directors	9	2	22.22%
Key Management Personnel	14 ²	4	28.57%

Turnover Rate

Employees	FY 2023-24 ³	FY 2022-23	FY 2021-22
Male	13%	14%	18%
Female	18%	17%	24%
Total	14%	15%	19%

Workers	FY 2023-24 ⁴	FY 2022-23	FY 2021-22
Male	11%	17%	12%
Female	18%	42%	31%
Total	11%	19%	14%

Holding, Subsidiary and Associate Companies (including joint ventures)

Names of holding / subsidiary / associate companies / joint ventures are as follows:

Sr. No.	Name of the Holding/Subsidiary/Associate/ Companies / Joint Ventures (A)	Indicate whether the Holding/ Subsidiary/ Associate/ Joint Venture	% Of shares held by Listed Entity	Does the Entity indicated at column A, participate in the Business Responsibility Initiatives of the Listed Entity? (Yes/No)
1.	GlaxoSmithKline PLC indirectly holds 75% shares in your company	Holding	75%	No
2.	Biddle Sawyer Limited.	Subsidiary	100%	Yes

¹ All unionized workers are classified as permanent workers

² This includes the Managing Director and a Whole-time Director

³ Turnover data reported does not include voluntary retirement, death and retirement

⁴ Turnover data reported does not include voluntary retirement, death and retirement

CSR Details

CSR is applicable as per section 135 of Companies Act, 2013. Your company's total spending on CSR is 2% of the average net profit in the previous three financial years. The CSR expenditure for the reporting year is INR 1,629.02 lakhs.

- (i) Turnover: INR 3,40,725 Lakhs
- (ii) Net worth: INR 1,78,409 Lakhs

The detailed report on the CSR programmes undertaken during the year has been provided in Annexure 'C' to the Director's Report.

The foundation of a sustainable society rests on healthy and empowered communities. Your company's CSR approach aims to address and bridge the gap in access and affordability to basic services for underprivileged and disadvantaged communities in India. Quality education and accessible healthcare infrastructure are core focus areas of your company's CSR activities. Our aim is to provide ample and equitable opportunities of growth and development for our communities, further contributing to the creation of a sustainable society. For FY 2023-24, our CSR activities have created long-term positive impact for marginalized communities across India, touching 35,571 lives. In FY 2023-24, your company has been awarded the following for positive social impact:



1. **'Best Education Initiative of the Year 2024'** by the Indian Social Impact Awards
2. GSK Scholars programme has been named as **'CSR Project of the year 2023'**
3. **Bronze award in the 'CSR Women and Child Health'** category at the 7th Edition of the CSR Health Impact Award 2023

Transparency and Disclosure Compliances

Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct:

Complaints filed for FY 2023-24 and FY 2022-23 have been provided in the graphs below. All resolved complaints were closed within stipulated timelines. Your company remains focused on resolving all pending complaints in a timely manner.

(*Note: Only those complaints from customers that relate to product quality are disclosed in the below chart. There may be more complaints from customers which may not be related to product quality. However, they are not disclosed here.)



Overview of the Entity's Material Responsible Business Conduct Issues

Material issues identified below are those that pose the most significant risks and opportunities to our business, and upon which your company has the most significant impact. These ESG issues play a critical role in decision making and devising of your company's strategy for long-term value creation for all stakeholders.

Material Issues	Risk / Opportunity	Rationale for Identifying as Risk	Management Approach	Implications of the Risk or Opportunity (Negative/ Positive)
Financial Controls and Reporting	Risk	Non-compliance with existing or new financial or new ESG reporting, and disclosure requirements, laws and regulations could materially and adversely affect our financial results and reputation. Failure to comply with applicable laws and regulations could result in GSK being investigated by relevant government agencies and authorities and/or in legal proceedings against us.	Your company maintains a control environment designed to identify material errors in financial reporting. Further, your company follows a standardised global financial reporting operating model, subjected to necessary audit procedures.	Negative
Commercial Practices	Risk	Failure to engage in activities that are consistent with the letter and spirit of the law, or the Group's requirements relating to commercial practices could materially and adversely affect our ability to deliver our strategy and long-term priorities. It may also result in ineffective treatment of patients, regulatory/legal action, financial repercussions, and reputational harm.	Your company's business unit risk management and compliance boards oversee commercial activities and their monitoring programmes. All promotional materials and activities must be reviewed and approved according to our policies and standards and conducted in accordance with local laws and regulations. All employees are also trained on relevant information. Annual audits are undertaken by internal Audit and global audit teams to provide assurance on the effectiveness of controls.	Negative
Legal Matters	Risk	Failure to mitigate legal risk could expose your company and associated persons to governmental investigation, regulatory action, and civil and criminal liability. In addition, failure to manage legal risk could have substantial implications for GSK's reputation and the credibility of senior leaders. It might erode investor confidence in your company's governance, risk management and future performance, and have a consequential negative impact on share performance. It could also lead to the imposition of significant financial penalties and the imposition of additional reporting obligations.	Your company's Group General Counsel oversees and is accountable for all legal matters. We have enterprise anti-bribery and corruption, competition law and sanctions control frameworks and programmes designed to ensure compliance with applicable laws and regulations, building on our Code, culture and business standards, and monitor and adapt to evolving regulations and our business activities. Your company regularly provides anti-bribery and corruption, competition law and sanctions training to employees, and relevant complementary workers and third parties in accordance with their roles, responsibilities and risks they face.	Negative
Data Ethics and Privacy	Risk	Increases in the volume of data processed and advances in technology have resulted in a greater focus on data governance and the ethical use of personal information, over and above compliance with data privacy laws. Non-compliance with data privacy laws could lead to harm to individuals and GSK. It could also damage trust between GSK and individuals, communities, business partners and government authorities.	Your company has a global data privacy policy and a global risk management structure comprising of the global Head of Digital, Privacy and Cyber Security with accountability for designing and implementing the control framework.	Negative

Material Issues	Risk / Opportunity	Rationale for Identifying as Risk	Management Approach	Implications of the Risk or Opportunity (Negative/ Positive)
Environment, Health, and Safety (EHS)	Risk	Failure to manage EHS risks could lead to significant harm to people, the environment and the communities in which we operate, fines, inability to meet stakeholder expectations and regulatory requirements, litigation or regulatory action, and damage to the company's reputation, which could materially and adversely affect our financial results	Your company has an effective control framework 'in-place' and 'in-use' to manage EHS risks and impacts. Function leaders ensure that the EHS control framework is implemented effectively in their respective business area. Every employee and qualified contractor acting on behalf of GSK is personally responsible for ensuring that they follow all applicable local standard operating procedures. Our risk-based, proactive approach is articulated in our global EHS policy and detailed in our global EHS standards, against which we audit all our operations to ensure compliance.	Negative
Supply Continuity	Risk	Disruption to our supply chain can lead to product shortages and product recalls, regulatory intervention, reputational harm and lost sales revenue.	Supply chain organisation closely monitors and reviews the inventory status and delivery of our products. Your company also has Crisis management and business continuity plans in place across supply chains, which include authorised response and recovery strategies, key areas of responsibility and clear communication routes.	Negative
Product Quality	Risk	Failure to maintain high standards of quality in products has an adverse impact on patient health, launch delays, product shortage and recalls. The company may also face severe regulatory, financial and reputational consequences due to compromised patient and safety and low-quality products. In order to cater to our patients in an effective and safe manner and enhance our business performance, strict adherence to high quality standards is a critical priority.	Your company aligns an extensive global network of quality and compliance professionals from site-level to senior management within each business unit to provide oversight and assist with the delivery of quality performance and operational compliance. This management oversight is delivered through a hierarchy of quality councils and a Global Head of Quality. Through a risk-based approach, your company assesses and manages third party suppliers that provide materials used in our finished products including monitoring third party labs and how they are independently checking goods. We expect contract manufacturers that make our products to comply with GSK standards and regularly conduct audits to provide us with assurance.	Negative

Material Issues	Risk / Opportunity	Rationale for Identifying as Risk	Management Approach	Implications of the Risk or Opportunity (Negative/ Positive)
Patient Safety	Risk	<p>The most important consequence of ineffective pharmacovigilance is the potential for harm to patients. Furthermore, non-compliance with laws and regulations on pharmacovigilance could result in inspection findings, regulatory scrutiny, civil or criminal sanctions and temporary/permanent loss of product marketing authorisation.</p>	<p>Our Chief Medical Officer is accountable for the Patient Safety enterprise risk and human safety matters, in collaboration with the Head of Global Safety. A cross-enterprise safety governance board oversees implementation of our control framework, including risk management. Our Global Safety Board ensures that we address human safety proactively throughout a product's lifecycle. Our global policy on management of human safety information requires that all employees immediately report issues relating to the safety of our products. Our third-party risk management framework supports us in identifying and training any third parties who may encounter human safety information.</p>	Negative
Scientific Patient Engagement	Risk	<p>Failure to engage in activities that are consistent with the letter and spirit of the law or the Group's requirements relating to scientific engagement practices could materially and adversely affect our ability to deliver our strategy and long-term priorities. It may also result in reputational harm.</p>	<p>Company's business unit risk management and governance oversee scientific and patient engagement activities and their monitoring programmes. All non-promotional materials and activities must be reviewed and approved according to our policies and standards and conducted in accordance with local laws and regulations. All employees are also trained on relevant information.</p> <p>Annual audits are undertaken by internal Audit and global audit teams to provide assurance on the effectiveness of controls.</p>	Negative

Section B: Management and Process DisclosuresSection

The section aimed at helping businesses demonstrate the structures, policies and processes put in place towards adopting the NGRBC Principles and Core Elements.

Disclosure Questions	P1	P2	P3	P4	P5	P6	P7	P8	P9
	Ethics and transparency	Product responsibility	Human resources	Responsiveness to stakeholders	Human rights	Protect & restore environment	Public policy advocacy	Inclusive growth	Customer engagement

Policy and Management Processes

1.	a.	Whether your entity's policy/policies cover each principle and its core elements of the NGRBCs. (Yes/No) ⁵	Y	Y	Y	Y	Y	Y	Y	Y
	b.	Has the policy been approved by the Board? (Yes/No)	Y	Y	Y	Y	Y	Y	Y	Y
	c.	Web link of the policies, if available	All business responsibility policies can be found on our website: GSK India Policies and Shareholder Information/ Policies .							
2.		Whether the entity has translated the policy into procedures. (Yes / No)	Y	Y	Y	Y	Y	Y	Y	Y
3.		Do the enlisted policies extend to your value chain partners?	Y	Y	Y	Y	Y	Y	Y	Y

4. Name of the national and international codes/certifications/labels/standards (e.g., Forest Stewardship Council, Fairtrade, Rainforest Alliance, Trustee) standards (e.g., SA 8000, OHSAS, ISO, BIS) mapped to each principle.

Your company is a signatory to the Organization of Pharmaceutical Producers of India (OPPI), Code of Pharmaceutical Practices based on the International Federation of Pharmaceutical manufacturers and Associations (IFPMA) Code.

We are also signatory to the AMR (antimicrobial resistance) Industry Alliance's Antibiotic Manufacturing Framework, which is one of the largest private-sector coalitions set up to provide sustainable solutions to curb AMR and wastewater discharge limits.

For more details refer to Principle 7.

5. Specific commitments, goals and targets set by the entity with defined timelines, if any, and performance of the entity against the specific commitments, goals, and targets along with reasons in case the same are not met.

a. Nashik Plant

Key Indicators	2023 ⁶ - Target	2023 ⁷ - Results	2022 ⁸ - Target	2022 ⁹ - Results
Energy Reduction	3.1%	3.3%	4%	9.6%
Water reduction	5%	5.6%	5%	11.6%
Waste reduction (hazardous)	4%	21% ¹⁰	1%	4%
Health & Wellbeing - Gold certification score	76.5	76.5	81	81

⁵ The GSK Code of Conduct covers all NGRBC Principles and their core elements as approved by the Board of Directors. Standalone policies are available on the company intranet

⁶ Calendar Year

⁷ Calendar Year

⁸ Calendar Year

⁹ Calendar Year

¹⁰ Waste reduction is calculated for the calendar year as per the GSK waste and circularity definitions where any non-hazardous waste reused for its intended usage is not termed as waste.

b. Corporate Office

Key Indicators and Targets Set	FY 2023-24 Performance
<p>Your company has set internal targets for improving the mental well-being of employees</p>	<ul style="list-style-type: none"> Your company has implemented multiple initiatives for enhanced mental wellbeing of its workforce. This includes an e-learning module called Mental Health Matters and live and recorded mindfulness sessions available on a 24*7 basis available in different languages.
<p>Your company intends to improve the physical and nutritional well-being for more than 30% of its workforce.</p>	<ul style="list-style-type: none"> Your company continues to make focused efforts for through the preventive healthcare programme – Partnership for Prevention. This programme offers 40 preventive healthcare services including both child and adult immunization, comprehensive cardiovascular health and diabetes screening, communicable disease assessments, cancer and HIV screening services and dedicated initiatives for tobacco cessation. Furthermore, annual health check-ups are also undertaken as part of this programme. Achieved Gold Status on Asia Health and Wellbeing leadership dashboard
<p>Your company has set global safety improvement targets by way of standardized operating procedures contained in the Life-Saving-Rules (LSR)</p>	<ul style="list-style-type: none"> All employees received quarterly trainings on pertinent safety topics through online platform. Additionally, behind the wheel face-to-face Defensive Driving Techniques training was imparted to certain field employees wherein they were given improvement feedback on their driving behavior. Your company’s Life Saving Rules were actively promoted to raise awareness among employees about 12 critical hazards and preventive measures to avoid injuries. Of 34 Incidents reported in FY 2023-24, 30 have been successfully resolved through our central online platform and lessons learnt will be used to identify targeted interventions for FY 2024-25.

c. Other Commitments

Key Indicators and Targets Set	FY 2023-24 Performance
<p>The company is committed to reducing the environmental footprint from the production of antibiotics at the Nashik and third-party manufacturers’ sites by controlling the release of antibiotics into the environment within the science-driven, risk-based discharge limits.</p>	<ul style="list-style-type: none"> Your company is a signatory to the AMR (antimicrobial resistance) Industry Alliance’s Antibiotic Manufacturing Framework. The focus of this private sector coalitions is to provide sustainable solutions to curb AMR and wastewater discharge limits. AMR analysis of wastewater has also been undertaken at Nashik site of 6 antibiotics. This has enabled discontinuation of treating contaminated wastewater through Effluent Treatment Plants.
<p>Water risk assessments for its plants and Contract Manufacturing Operations (CMO) sites</p>	<ul style="list-style-type: none"> Based on water risk profile analysis and the Aqueduct tool WWF water risk assessment tool, CMO’s are assessed for their exposure to water risk. In the current year 4 CMO’s were identified for this assessment. 1 CMO was identified for water KAIZEN. Your company has also begun monitoring CMO sustainability initiatives. Your company has undertaken an assessment of the sites water consumption and discharge practice and then identify water consumption reduction opportunities. Efforts have also been made to select and develop alternate sites for meeting water requirements in the long run.

Your company also has Quality KPIs and Improvement Plans for each financial year, and performance against the same is strictly tracked and monitored through a robust governance mechanism.

6. Statement by director responsible for the business responsibility report, highlighting ESG related challenges, targets and achievements

Our purpose is to unite science, technology and talent to get ahead of disease together. Your company is strongly committed to being a truly sustainable and responsible business and continues to make focused efforts in that direction. We remain focused on building a resilient product portfolio, aligned with manufacturing competencies and Healthcare Professional engagement is enhanced by adoption of digitalization and emerging technologies. Your company also places strong focus on protecting the environment in and around our operations and contributing to social development. There is strong recognition of the role we must play as a responsible corporate citizen and our duty to drive and deliver long term value creation for all our stakeholders.

Being commercially successful and operating responsibly is how we will generate sustainable returns for our shareholders and deliver on our purpose. We aim to bring differentiated, high quality and essential pharmaceuticals and vaccines to as many people as possible. Our four priorities – Innovation, Performance, Trust and Culture– help us realize our ambition for patients and drive robust growth for our shareholders and people to positively impact the health of millions of people. The three core pillars of our culture are – “Ambitious for patients”, “Accountable for impact” and “Doing the right thing”.

7. Details of the highest authority responsible for implementation and oversight of the Business Responsibility policy/policies

Name: Mr. Bhushan Ashikar

Designation: Managing Director

Director Identification Number (DIN): 09112346

8. Does the entity have a specified Committee of the Board / Director responsible for decision making on sustainability issues? If yes, provide details.

Yes, your company’s Risk Management committee has been provided with the mandate of overseeing all issues with respect to sustainability and Environment, Social and Governance (ESG) issues.

9. Details of Review of NGRBCs by your company:

Performance against policies and follow up action	Performance against policies and ensuring alignment with
Compliance with statutory requirements of relevance to the principles, and the rectification of any non-compliances	statutory requirements is governed by internal mechanisms covered under these policies. Any non-compliances are flagged as per the centralized system for appropriate action.

10. Has the entity carried out independent assessment / evaluation of the working of its policies by an external agency? If yes, provide name of the agency.

No, your company has not undertaken an independent assessment / evaluation of its policies by an external agency. Periodic internal audits are undertaken to ensure the effective working of all policies and strict alignment with internal protocols and guidelines.

Section C: Principle-wise Performance Disclosure

This section is aimed at helping companies demonstrate their performance in integrating the Principles and Core Elements of the National Guidelines on Responsible Business Conduct (NGRBC).

Principle 1: Businesses should conduct and govern themselves with integrity, and in a manner that is Ethical, Transparent and Accountable.

Integrity, accountability, and transparency forms the foundation of the manner and mode in which your company conducts business. The GSK Code of Conduct ('Code') is the guiding framework for ethical business conduct, and strict alignment is maintained with the values and expectations set forth within the Code. In addition, our external interactions to enhance the understanding and appropriate use of GSK medicines and vaccines for the benefit of individual patients and populations are governed by the Code of Practice for Promotional and Non-promotional External Interactions.

Your company is also committed to high standards of quality of our products to impact human health positively. The Pharmacovigilance and Quality teams maintain strict vigilance of all processes to ensure safe and high-quality products. In conjunction with our supporting policies and procedures, enables us to conduct our external interactions in a way that adheres to relevant laws, regulations, and external codes.

Our business strategies are patient-centric, and we strive to foster a respectful and safe environment for all our employees and society at large. We also ensure strict alignment with applicable local laws, regulations, industry codes and requirements to deliver the best products and services to our stakeholders.

Essential Indicators

1. Percentage coverage by training and awareness programmes on any of the principles during the financial year.

Your company undertakes training for your workforce on Information Security, Privacy, Anti-Bribery and Corruption, Inclusion & Diversity, and Conflicts of Interest. Your company also undertook a driver safety awareness session for all field employees during the FY 2023-24 annual sales meet.

Category	Total Number of Training and Awareness Programmes held	Topics/Principles covered under the Training and its Impact	% Of persons in a respective category Covered by the Awareness Programmes
Board of Directors	1	Board of Directors sign off on Code of Conduct annually and a "No Conflict of Interest" declaration	100%
Key Managerial Personnel		<ul style="list-style-type: none"> Living Our Code Creating an inclusive workplace - Diversity and Inclusion Anti-bribery and corruption, Competition Law 	
Employees other than Board of Directors and KMPs	4	<ul style="list-style-type: none"> Protecting GSK everyday - Protecting GSK values, data privacy and information risk, Phishing Trainings Prevention of Sexual Harassment: Annual e-learning Refresher module for every employee Complaint Handling and Reporting of Counterfeit Products 	100%
Workers	12	Health and safety training: 12 types of health and safety trainings were provided to management and non-management staff. Contractor/ non-permanent workers were provided with 6 types of training	100%

2. Details of fines/ penalties/ punishment/ award/ compounding fees/ settlement amount paid in proceedings (by the entity or by directors/ KMPs) with regulators/ law enforcement agencies/judicial institutions in the financial year.

For FY 2023-24, there were no instances of fines/penalties, settlement or compounding fees. Additionally, there were no cases of imprisonment or punishment for FY 2023-24.

3. Of the instances disclosed in Question 2 above, details of the Appeal/ Revision preferred in cases where monetary or non-monetary action has been appealed.

Since your company was complaint, there were no cases of appeal/revision for FY 2023-24.

4. Does the entity have an anti-corruption or anti-bribery policy? If yes, provide details in brief and if available, provide a web link to the policy.

Yes, your company has established detailed policies and processes to address any concern with respect to and prevent bribery and corruption. These include a comprehensive Anti-Bribery and Corruption (ABAC) policy, SOP on Managing Third Party risks, Guidance on External Experts with influence on GSK's business, Gifts, Entertainment and Hospitality Policy and Conflicts of Interest Policy, among other policies and guidance. Mandatory ABAC training is also provided on a periodic basis to critical categories of employees and high ABAC risk third parties.

Your company has also devised an Anti-Bribery and Anti-Corruption Program. The program includes the ABAC Written Standards, developed to aid internal and external parties in understanding the risk of corruption and identify people's responsibilities to proactively address any potential or actual corruption.

5. Number of Directors/KMPs/employees/workers against whom disciplinary action was taken by any law enforcement agency for the charges of bribery/ corruption.

There were no instances of disciplinary action against Directors/KMPs/employees/workers for FY 2023-24 and FY 2022-23.

6. Details of complaints with regard to conflict of interest.

All related party transactions are pre-approved by the Audit Committee and the Board of Directors. No complaints with regard to conflict of interest were received in FY 2023-24 and FY 2022-23.

7. Provide details of any corrective action taken or underway on issues related to fines / penalties / action taken by regulators/ law enforcement agencies/ judicial institutions, on cases of corruption and conflicts of interest.

Since your company is compliant, there was no corrective action taken or underway for FY 2023-24.

8. Number of days of accounts payable {(Accounts Payable*365)/Cost of goods/services procured}:

Category	FY 2023-24	FY 2022-23
Number of days accounts of accounts payable	100	97

9. Open-ness of business

Provide details of concentration of purchases and sales with trading houses, dealers, and related parties along-with loans and advances & investments, with related parties, in the following format:

Parameter	Metrics	FY 2023-24	FY 2022-23
Concentration of Purchases	Purchases from trading houses as % of total purchase	NA	NA
	Number of trading houses where purchases are made from	NA	NA
	Purchases from top 10 trading houses as % of total purchases from trading houses	NA	NA

Parameter	Metrics	FY 2023-24	FY 2022-23
Concentration of Sales	Sales to dealers/distributors as % of total sales	97%	99%
	Number of dealers/distributors to whom sales are made	4,317	4,427
	Sales to top 10 dealers / distributors as % of total sales to dealers / distributors	5.15%	4.63%
Share of RPTs in	Purchases (Purchases with related parties/Total purchases)	35%	30%
	Sales (Sales to related parties / Total Sales)	0.01%	0%
	Loans & advances (Loans & advances given to related parties / Total loans & advances)	100%	100%
	Investments (Investments in related parties / Total Investments made)	1%	1%

Leadership Indicators

1. Awareness programmes conducted for value chain partners on any of the principles during the financial year.

- Training on anti-bribery and corruption is provided to all third-party partners, based on the level of risk (medium or high) and type of service to be provided, identified through the third-party risk assessment (TPRA) questionnaire. Online training via TRACE is the most suitable channel for providing ABAC training. On completion of training, the ABAC.tracetraining@gsk.com shares certificates and provides any other follow up required. Business owners remain accountable to ensure that their third-party partner is trained.
- Critical third-party contract manufacturers undergo periodic awareness and sensitisation programs on "Water Kaizen" (brainstorming on various water saving initiatives) and antimicrobial resistance (e.g., permissible discharge limits).
- Third-party contract manufactures have also been provided with training on Life Saving Rules, Contractor Safety, Laboratory Safety, Warehouse Safety, Permit to Work, Lock out and Tag Out.
- Communication on your company's business responsibility policies such as the Code of Conduct, prevention of sexual harassment, and Standard Operating Procedures (SOPs) for health and safety is provided to all third-party manufacturers.

2. Processes in place to avoid/ manage conflict of interests involving members of the Board.

Your company's Code of Conduct provides details on the measures to avoiding/managing conflict of interests involving members of the Board. All activities are assessed for potential conflicts and ensures that any actual, potential, or perceivable conflicts are declared and resolved before the initiation of any task or project. Further, all Directors sign the Code of Conduct and submit a "No conflict of interest" declaration annually.

Principle 2: Businesses should provide goods and services in a manner that is sustainable and safe

Quality, safety and consistent supply of your company’s products is a critical priority. Focused efforts are undertaken to provide effective solutions to all our patients and consumers. Robust quality management processes are strictly adhered to for the lifecycle of all our products across all stages of the supply chain.

Our patient centric approach forms the foundation of our approach to sourcing, manufacturing and marketing of all products. Several targeted measures have been instituted to detect, evaluate, and communicate benefits, risks, and potential safety concerns about our products. Your company’s Quality Management System and processes have been formalised in line with Good Manufacturing Practice (GMP) regulations and other good practice procedures for ensuring Product Quality. Strict compliance with this enables your company to provide customers with high quality and safe products.

Further, through a warehousing and distribution network comprising 20 CMOs, 23 Carrying and Forward Agents (CFAs), 2 central warehouses and over 5,300 stockists, your company is successfully able to provide timely superior patient service and satisfaction. Focused automation and digitalisation initiatives also support our mission to deliver excellence to our entire consumer base.

Since inception, your company has focused on driving and delivering positive and improved patient outcomes. All our products are developed with a focus on our patients and their wellbeing. Our product Trelegy Ellipta, India’s first single inhaler therapy (SITT) in a once-daily regime for chronic obstructive pulmonary disease (COPD) patients, exemplifying our ambition to provide greater access to world class medicine for all our patients. Similarly, our Nucala auto-injector formulation enables patients to self-administer Nucala without the need for hospital visits. The auto-injector provided ensures ease of compliance and access during emergency situations. In FY 2023-24, your company has significantly increased investments within our respiratory portfolio, further demonstrating our commitment to innovative products for greater patient care.

Your company introduced Shingrix in April 2023; this being the first time a vaccine was launched in more than seven specialities in the Indian market. Shingrix is accepted positively by Healthcare Professionals (HCPs) including super specialists, who cater to immunocompromised patients or patients at high risk due to immunosuppressive therapies. Further, your company is planning to partner with HCPs to create adult immunisation ecosystem so that a larger number of patients are safeguarded against the vaccine preventable diseases.¹¹

Essential Indicators

1. Percentage of capital expenditure (capex) investments in specific technologies to improve the environmental and social impacts of product and processes to total capex investments made by the entity.

Your company spent 30% and 11.5% of its total capex expenditure in technologies for improved environmental and social impact of products and processes for FY 2023-24 and 2022-23 respectively.

Initiative	Percentage of investment
Installation of solar system with a capacity of 1 Mega Watt	24%
Effluent Drainage replacement work	2%
Rainwater storage pond	2%
Online continue emission control system	2%
Tablet DCU for reduced emissions	1%
Retrofit Emission Control Device to DG sets	0.004%

2. Does the entity have procedures in place for sustainable sourcing? (Yes/ No). If yes, what percentage of inputs were sourced sustainably?

Your company is committed to adopting sustainable practices across the lifecycle of our products, including sourcing. Our approach to sustainable sourcing is guided by the Global Sustainable Sourcing Standard, containing a framework of environmental, social and ethical supply chain requirements to be met by 2030. Sustainable sourcing is a global target for all your company’s locations including purchases from contract manufacturing organisations. The following procurement key performance indicators and targets have been identified for 2024:

- 1,37,000 tonnes of CO2 e reduction from Scope 3
- 90% sustainable sourced paper packaging

¹¹ Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar 29;356(13):1338-43. doi: 10.1056/NEJMct066061. Lokeshwar MR, Agrawal A, Subbarao SD, Chakraborty MS, Ram Prasad AV, Weil J, Bock HL, Kanwal S, Shah RC, Shah N. Age related seroprevalence of antibodies to varicella in India. Indian Pediatr. 2000 Jul;37(7):714-9.

- 93% sustainably sourced palm oil
- 50% key suppliers to practice water stewardship
- 50% key material spend with approved sustainable sourcing action plan

3. Describe the processes in place to safely reclaim your products for reusing, recycling and disposing at the end of life, for (a) Plastics (including packaging) (b) E-waste (c) Hazardous waste and (d) other waste.

Your company’s approach to waste management prioritises reduction of waste and increasing the number of materials recovered through circular routes such as reuse or recycling. Guided by robust internal controls and processes and applicable laws and regulations, processes to safely reclaim our products for reuse, recycling and disposal at the end of life are strictly adhered to across your company’s operations.

All plastic waste including packaging is treated in line with Extended Producer Responsibility (EPR) obligations. Hazardous waste, e-waste and other waste is handled at the end of life in line with Rules of the Central Pollution Control Board and other applicable local laws and regulations.

We have also developed detailed Standard Operating Procedures (SOPs) for the handling of stock returns and destruction of products for Central Warehouses and CFAs. This includes all rejected, recalled, returned, expired, quarantined, counterfeit and falsified stock. These SOPs provide mandatory requirements for the effective management of product or stock destruction to minimize risks to patients or consumers and accurate stock reconciliation. All Central Warehouse personnel and CFAs are required to undertake training on these SOPs to ensure strict compliance.

4. Whether Extended Producer Responsibility (EPR) is applicable to the entity’s activities (Yes / No). If yes, whether the waste collection plan is in line with the Extended Producer Responsibility (EPR) plan submitted to Pollution Control Boards? If not, provide steps taken to address the same Extended Producer Responsibility (EPR) is applicable to the entity’s activities.

Your company undertakes disposal of all waste is undertaken in line with the EPR obligations put forth by the Central Pollution Control Board (CPCB). Waste generated across our operations is segregated and handed over to government-approved vendors for recycling and incineration as appropriate. However, in FY 2023-24 post consumer plastic packaging of GSK products were not reclaimed physically as the new Amendment of Plastic Waste Management Rules 2016 requires purchase of equal amount of plastic EPR credits (recycling/co-processing) for plastic packaging introduced in the market through our products. Accordingly for FY 2023-24, plastic credits (Category I: Rigid: 1210 MT, Category II: Flexible: 421 MT and Category III: MLP: 666 MT) shall be purchased from authorized Plastic Waste Processors. Further, the Centralized EPR Portal for Plastic Packaging was inactive for a period of four months. Once it is functional, the respective credits will be purchased from the Plastic Waste Processors and transferred to GSK account through the Centralized EPR Portal for Plastic Packaging.

Leadership Indicators

1. Has the entity conducted Life Cycle Perspective / Assessments (LCA) for any of its products?

Your company has not undertaken any Lifecycle Perspective/Assessments of any of its products in FY 2023-24.

2. Percentage of recycled or reused input material to total material (by value) used in production.

Not Applicable. Your company manufactures lifesaving formulations. Therefore, as required by Good Manufacturing Practices (GMP), your company does not use recycled or reused input material.

3. Of the products and packaging reclaimed at end of life of products, amount (in metric tonnes) reused, recycled, and safely disposed of.

Detailed SOPs and robust processes have been developed and implemented to take back all products that have expired or have suffered breakages. All products that have expired or are near expiry returned by the dealers/distributors to your company’s distribution warehouse/ CFAs. On collection, products are sent to authorised waste management agencies for incineration. Certificates of disposal are also obtained for quality control purposes.

	FY 2023-24		FY 2022-23	
	Recycled (MT)	Safely disposed (MT)	Recycled (MT)	Safely disposed (MT)
Plastics (including packaging)	- ¹²	-	912.49	453.42
Hazardous waste	0	280.1	0.60	158.43

¹² Once the EPR Portal is operational and the plastic waste processors are on boarded EPR Credits (Recycled/Co-processed) of equivalent quantity of plastic packaging introduced in the market shall be purchased.

Principle 3: Businesses should respect and promote the well-being of all employees, including those in their value chains

Our people form the bedrock of our commercial success and reputational growth. Your company's employees are recognised as assets and priority is given to creating a conducive working environment for them to flourish. As a modern employer, our efforts are focused on fostering a culture that prioritises the well-being of all our employees. This approach to employee management strengthens and nurtures our workforce, while also enabling your company to attract and retain highly skilled professionals, creating value for all our stakeholders.

Diversity, Equity and Inclusion (DEI)

Your company is an equal opportunity employer and is committed to creating a diverse and inclusive culture for all employees and workers to achieve their true potential. Our aim is to provide a working environment wherein our entire workforce feels valued and respected. The India Leadership Team (ILT) has formalised a roadmap in 2022 to focus on Women and the LGBTQ+ community.

Your company has set up two Employee Resource Groups (ERGs) – **Women's Leadership Initiative and Spectrum** – to provide for an enabling and safe environment that advocates for a diverse and inclusive workforce. These ERGs act as communication platforms for our workforce to provide their feedback on our processes and policies and report any concerns for timely redressal. Periodic updates are provided by the ERGs to the leadership team and collaborative discussions are undertaken for strategy development and addressing of any roadblocks effectively.

In 2022, your company introduced the Stronger Together Inclusion Awards, to recognize employees who have championed our inclusive culture, encouraging others to follow suit. Your company has also amended policies to support our diverse workforce, such as our Parichay Employee Referral Policy, Child Care Policy, Sabbatical Policy, and Parental Leave Policy, to incentivize diversity referrals, cater to the needs of mothers and single parents, and provide parental leave to all employees who are primary or secondary care givers, irrespective of their gender. Your company has also initiated Care of Family Member Leave for employees to take up to four weeks of leave for care of an immediate family member. Further, all employees also undergo awareness sessions on diversity and inclusion to create a safe and dignified working environment for all.

Employee Engagement and Well Being

Fostering a transparent culture that supports and prioritised two-way communication is a critical priority. Your company undertakes GSK Culture survey, Manager One80 survey and Listening sessions to encourage open and honest conversations. In FY 2023-24, an engagement rate of 92% was recorded through the GSK Culture Survey and a score of 4.2 out of 5 was recorded on the One80 Manager Survey. Additionally, Let's talk sessions with leaders, quarterly townhall and coffee sessions encourage expression, deliberation, and ideation in an open forum. Furthermore, Performance with Choice is offered to all office-based workforce to decide how they can work in a way that supports individual and collective performance and personal wellbeing.

Learning and Development:

Supporting the right capabilities and providing for adequate opportunities of learning and development is central to your company's approach to talent management. Focused programmes are undertaken to enhance the capabilities of our workforce and provide them with necessary skills for career development. Your workforce continues to benefit from our in-built flagship leadership development programmes, Lakshya and Catalyst. In FY 2023-24, 90 employees have benefited through these programmes. Your company also implements Future Leader Programme, a flagship early talent initiative, to recruit skilled talent from prestigious institutions by offering them diverse and rewarding roles across business divisions.

Your company launched a new learning initiative in FY 2023-24 to provide functional and leadership training – Sales People Managers Capability Development Program, Aspire. A total of 44 Second Lines Sales Leader and 303 First Line Sales Leader provided with training through this initiative.

Your company also offers global capability programmes such as First Line Leader to catalyse and upskill your first line sales leaders. Other global and regional leadership development programs include Emerging Markets Talent forum, Accelerating Differences, Emerging Markets Trailblazers Programme for Leadership Development.

On the go learning is also provided to all employees on a variety of subject areas under Business Skills, Leadership Skills and Technical Skills through a virtual university campus, called the Key Growing Campus. In addition to this, employees can also access learning modules from external partners, such as LinkedIn Learning, Harvard Leading Edge, Get Abstract, Globe Smart, Henry Stewart Talks, Education First and Career Innovation.

Vigil Mechanism

Your company is committed providing for a safe and healthy working environment for its entire workforce. Focused efforts are undertaken to foster an open culture, characterised by integrity and accountability. Our people are encouraged and trained to act in an ethical and honest manner and openly speak up against any malpractices that they identify.

Your company has a dedicated Speak-Up portal for all our stakeholders to raise opinions and concerns. We also have a Whistle-blower policy, and it provides a mechanism for all stakeholders to approach the local/group management or the Chairperson of the Audit Committee to raise issues of concern. Your company also strongly advocates for anti-retaliation. Robust internal mechanisms, as detailed in our Safeguarding people who report unethical or illegal conduct policy, provide for protection of the identity of a complainant and prevention of any retaliation against them.

Awards

Your company has received these recognitions in FY 2023-24:

1. Certified as **Great Place to Work®**
2. Accredited for **'Inclusive Practices by the Great Place to Work Institute'**
3. **'India's Most Attractive Employers in 2023'** by Universum
4. Recognised as one of the **'Top 100 companies in India for Women'** by Avtar and Seramount Study and **'Top 24 Employers of the Future in 2023'** by Fortune India & Work Universe
5. **First Runner-Up title in the 'Best Employer for Women'** category at the ASSOCHAM (Associated Chambers of Commerce and Industry of India) awards
6. Named as one of the **'Best Organisations for Women 2023'** by the Economic Times

Essential Indicators

1. a. Details of measures for the well-being of employees and workers.

All permanent employees and workers are covered by well-being measures such as health insurance, accident insurance, maternity benefits (if applicable), paternity benefits (if applicable), day care facilities (if applicable) and life term insurance.

b. Spending on measures towards well-being of employees and workers

Category	FY 2023-24	FY 2022-23
Cost incurred on wellbeing measures as a % of total revenue of the company	0.48 %	0.49%

2. Details of retirement benefits.

Benefits	FY 2023-24			FY 2022-23		
	No. of Employees Covered as a % of Total Employees	No. of Workers Covered as a % of Total Workers	Deducted and Deposited with the Authority (Y/N/N.A.)	No. of Employees Covered as a % of Total Employees	No. of Workers Covered as a % of Total Workers	Deducted and Deposited with the Authority (Y/N/N.A.)
PF	100%	100%	Y	100%	100%	Yes
Gratuity	100%	100%	Y	100%	100%	Yes
ESI	1%	0%	Y	1%	0%	Yes

3. Accessibility of workplaces

Your company's head office at Worli, Mumbai is accessible to differently abled employees and workers.

4. Equal opportunity policy as per the Rights of Persons with Disabilities Act, 2016

Yes, your company is an Equal Opportunity and Affirmative Action Employer. We are committed to fostering a diverse and inclusive workforce and providing for equal opportunities of growth and development as enshrined in our Code. Our endeavour remains to create a merit-based organisation and prevent any possible discrimination.

5. Return to work and Retention rates of permanent employees and workers that took parental leave.

Gender	Permanent Employees		Permanent Workers	
	Return to Work Rate	Retention Rate	Return to Work Rate	Retention Rate
Male	88%	82%	-	100%
Female	80%	62%	75%	80%
Total	87%	79%	75%	99%

6. Is there a mechanism available to receive and redress grievances for employees and workers?

Your company encourages the entire workforce to raise and report any concerns and grievances with their managers, Legal, Human Resource and Ethics and Compliance representatives. We also provide for an anonymous grievance redressal channel through our Speak Up platform for anyone inside or outside GSK to report any misconduct, violation of law or breach of our Code. All complaints are registered and tracked through your company's Incident Management System, i-Sight. We also have a zero-tolerance approach for retaliation against individuals who report concerns in good faith.

Your company has also formalised four zonal committees who convene monthly along with trade union members to identify, acknowledge, address and redress grievances. Additionally, all unionized workmen can raise grievances through the Speak Up Channel or through the Union Office Bearers. Subsequently, Union Office Bearers raise these concerns with Human Resources and monthly meetings between the Union, Value Stream and other functional heads. Furthermore, your company also conducts monthly special sessions – Tea with Site Director – for shopfloor employees to directly engage with the Site Director and report any concerns.

Your company's Internal Committee addresses all complaints with respect to incidences of sexual harassment in a sensitive and timely manner.

7. Membership of employees and workers in association(s) or Unions recognized by the listed entity.

Your company recognises the right to freedom of association and collective bargaining of all Medical Business Associates (MBAs) and workmen. We engage with several unions representing MBAs of Pharmaceutical Marketing at sales locations (Delhi, Kolkata, Mumbai, Chennai) and the union representing workmen at the Nashik plant.

Category	FY 2023-24			FY 2022-23		
	Total Employees/Workers (A)	No. of Employees / Workers who are part of association(s) or Union (B)	% (B / A)	Total Employees/Workers (C)	No. of Employees / Workers who are part of association(s) or Union (D)	% (D / C)
Male	1,451	1,451	100%	1,809	1,809	100%
Female	185	185	100%	178	178	100%
Total Permanent Workers	1,636	1,636	100%^x	1,987	1,987	100%

8. Details of training given to employees and workers.

Health and safety: All management and non-management staff at the Nashik plant have been provided with 12 types of health and safety trainings in FY 2023-24 and FY 2022-23. The list of trainings includes first aid training, safety induction and refresher, role/function based specific training, firefighting training, stop for safety sessions, Life Saving Rules, significant incident fatality training, emergency preparedness, incident investigation, risk assessment, diet, health, heat wave, seasonal flu, etc.

100% of non-permanent staff were provided with 6 types of training for FY 2023-24 and FY 2022-23. Your company also conducted in-person and virtual driver safety awareness sessions covering pertinent subjects for all field-based personnel. Additionally, your company incorporated gamification initiatives focused on driver safety awareness for all field employees during the annual sales meeting held in the fiscal year 2023-24. To facilitate the desired behavioural change, your company also implemented a mobile application-based intervention aimed at fostering safe driving practices. Furthermore, safety equipment such as reflective jackets and high-visibility LED blinkers were distributed to all field personnel, emphasizing the importance of prioritizing safety before commencing any journey.

Skill upgradation: For your company, elevating the capabilities of your workforce and fostering continuous learning opportunities lies at the core of your talent management strategy. Your company has designed targeted programs to augment skill sets and fuel career advancement. Our flagship leadership development initiatives, Lakshya and Catalyst, continue to enhance employee capabilities. Moreover, our Future Leader Programme identifies talent from esteemed institutions, offering them diverse roles across divisions. In FY 2023-24, we introduced the Sales People Managers Capability Development Program, Aspire, to provide specialized functional and leadership training. Additionally, our global capability programs like First Line Leader aim to accelerate the growth of our sales leaders. Regional programs such as the Emerging Markets Talent forum and the Emerging Markets Trailblazers Programme further enhance leadership excellence.

To ensure learning is seamlessly integrated into the workflow, our virtual university campus, the Key Growing Campus, delivers on-the-go training in Business, Leadership, and Technical Skills. Furthermore, we collaborate with esteemed external partners such as LinkedIn Learning and Harvard Leading Edge to provide a diverse range of learning modules. This strategic approach underscores our commitment to nurturing a skilled and agile workforce poised for success.

Skill Upgradation	FY 2023-24			FY 2022-23		
	Total (A)	Number (B)	Percentage (B/A)	Total (A)	Number (A)	Percentage (B)
Employees						
Male	1324	1305	98.56%	1450	697	48%
Female	251	248	98.80%	243	190	78%
Total	1575	1553	98.60%	1693	887	52%
Workers						
Male	1451	1434	98.83%	1809	380	21%
Female	185	179	96.76%	178	98	55%
Total	1636	1613	98.59%	1987	478	24%

9. Details of performance and career development reviews of employees and worker.

All your company’s employees are expected to prepare individual development plans and formalise performance and development goals to align their career objectives to GSK’s IPTC (Innovation, Performance, Trust, Culture) priorities. At the end of a performance cycle (January to December), each employee is reviewed on their performance for the year, mapped to expectations set at the start of the cycle. Based on the review, rewards like increments are accordingly determined. For Calendar Year 2024, 100% of your company’s eligible workforce at the Nashik plant and 99% employees at the corporate office completed their development goals.

Further, through your company’s Manager One80 survey, all managers are provided with an opportunity to gather honest feedback and identify areas of improvement. We also implement Global Employee Recognition to recognise employees championing GSK’s priorities and objectives.

10. Health and safety management system.

- a. Whether an occupational health and safety management system has been implemented by the entity? (Yes/ No). If yes, what is the coverage of such a system?

Yes, your company has a health and safety management system in place, covering all employees and locations that we operate in. We are committed to providing a safe working environment for our entire workforce and make focused efforts to identify and mitigate any potential or actual risks. We also provide for adequate training and awareness sessions for our workforce to foster and strengthen a culture of safety.

- b. What are the processes used to identify work-related hazards and assess risks on a routine and non-routine basis by the entity?

Your company has made significant investments in world class facilities and infrastructure to reduce the threat of work-related hazards on site. Additionally, our Safety Leadership Experience (SLE), a companywide EHS programme, is implemented to embed safety across your company's operations. This programme aims to integrate high risk reduction activities within our daily systems and processes. Through the implementation of Gemba, we mitigate the identified risks by providing effective safety controls following the hierarchy of safety controls.

Furthermore, our Life Saving Rules (LSR) programme ensures that our entire workforce is aware of and follows most critical safety rules. Under the LSR safety campaigns, impact communication on LSR is provided to create awareness on the importance of the same. Further, periodic meetings and awareness initiatives are implemented to identify potential risks and provide information on mechanisms to report the same.

Detailed SOPs in line with EHS Standard 2.01 Risk Assessment and Management have been developed for your company's operations at the Nashik Site. Your company also undertakes several forms of risk assessment to identify risks in a timely manner and develop appropriate and effective mitigation measures.

Further, policies and processes have also been implemented to undertake safety assessments of key third party suppliers at the time of onboarding and at periodic intervals thereafter.

- c. Whether you have processes for workers to report the work-related hazards and to remove themselves from such risks.

Work related hazards on site can be reported through detailed and comprehensive internal controls and processes. Your company implements Zero Action Promotion (ZAP) at the Nashik Site for reporting and tracking workplace hazards.

- d. Do the employees/ workers of the entity have access to non-occupational medical and healthcare services?

- Medical insurance for occupational as well as non-occupational healthcare services are provided to all employees. In a step towards an inclusive and diverse work culture, gender reassignment surgery is also included within the list of covered services. Negotiated premiums are also offered to enable our employees to increase their medical coverage and include their parents.
- Our continued efforts through the preventive healthcare programme, Partnership for Prevention (P4P), creates significant positive impact for all our permanent employees and their dependants. This program provides 40 preventive healthcare services at minimal or no cost. Benefits include preventive screening for cancer and diabetes, paediatric consultation, adult and child immunization programs, prenatal care programs and support for tobacco cessation.
- Your company also provides Group Life Insurance and Accidental Life Insurance to all employees.
- Your company also has an Employee Assistance Program to support the mental well-being of employees and their immediate family members. This programme connects all employees with a 24*7 professional counsellor in an accessible, voluntary and confidential manner. We also undertake training to sensitize all employee to mental health and the importance of creating a conducive environment.

11. Details of safety-related incidents.

Nashik Plant

- **Two** work-related injuries have been reported for the current year, recording a Lost Time Injury Frequency rate of **2.1**. **No** work-related injuries were reported for the previous year.
- **No** fatalities or high consequence work-related injury or ill-health fatalities reported in current year or previous year.

Corporate Office

- **Thirty-four and one** work related injury reported in the current and previous reporting year respectively. The Lost Time Injury Frequency Rate for FY 2023-24 was **5.25**.
- **No** fatalities or high consequence work-related injury or ill-health fatalities reported in current year.

12. Describe the measures taken by the entity to ensure a safe and healthy workplace.

Your company has adopted a preventive approach to provide for a safe and healthy workplace. Our endeavour remains to provide for a workplace that is safe and devoid of any harm. Your company has launched Safety Leadership Experience (SLE) with the objective of embedding and reinforcing safety culture across our operations. Focused awareness activities are also carried out on our Life Saving Rules and key risks, such as operating machinery or driving. We also undertake 'Energy for Performance' and 'Personal Resilience' training programmes to foster employee health, wellbeing, and resilience. Regular consultations are also conducted with the employees to improve their experience at work.

13. Number of complaints on the following made by employees and workers.

For your company's corporate office, fifteen complaints were filed during FY 2023-24 on matters relating to working health & safety on near miss incidents and observations. All complaints were satisfactorily resolved by your company. For Nashik site, no such complaints were filed in FY 2023-24 and FY 2022-23.

14. Details on Assessments for the year.

Health and safety practices	Periodic internal assessments are undertaken at all offices and plants on health and safety practices. Strict compliance is maintained with all applicable laws and regulations.
Working Conditions	There is no specific assessment done for the same. However, the entity complies with all laws and regulations relating to fair working conditions and labour laws.

15. Provide details of any corrective action taken or underway to address safety-related incidents (if any) and on significant risks / concerns arising from assessments of health & safety practices and working conditions.

Since your company is compliant, there was no corrective action suggested by an auditing or inspecting authority for FY 2023-24.

Leadership Indicators**1. Does the entity extend any life insurance or any compensatory package in the event of death?**

Yes, Group Life Insurance coverage and Accidental Life Insurance coverage is extended to your employees and workers.

2. Provide details on the measures undertaken by the entity to ensure that statutory dues have been deducted and deposited by value chain partners.

Payment of statutory dues is included as a contractual requirement with all value chain partners. Non-payment of statutory dues leads to termination of the agreement.

3. Provide the number of employees/ workers having suffered high consequence work-related injury/ fatalities who have been rehabilitated and placed in suitable employment, or whose family members have been placed in suitable employment.

No high consequence work-related injury/fatalities were reported for FY 2023-24 and FY 2022-23.

4. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No)

Transition Assistance is provided for employees whose employment is terminated due to job redundancies.

5. Details on assessment of value chain partners.

All the value chain partners undergo third party risk assessment (TPRA) on induction and at least once in every three-years/as required by business owners. Insights from this assessment helps your company to identify any potential or actual risks associated in dealing with such vendors on parameters like environment, health & safety, labour rights, Privacy, crisis & continuity management, ABAC, etc. Based on assessment findings, mitigation actions are agreed upon with identified vendors and implemented. Further, background checks are also conducted for timely identification of any red flags associated in dealing with such vendors. All vendors are onboarded only post successful completion of the TPRA.

Your company also undertakes a quarterly review of any health and safety incidents if any, for key CMOs. Additionally, other programs relating to antimicrobial resistance, process safety management, and chemical exposure are undertaken. An internal committee for all matters relating to health and safety has been established at all key CMOs comprising of site management and workers.

In FY 2023-24, four of your company's key CMOs were assessed on health and safety and working conditions.

6. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners.

Since your company is complaint, there was no corrective action suggested by an auditing or inspecting authority for FY 2023-24. Based on findings from internal assessments undertaken in FY 2023-24, your company has implemented EHS corrective action plans for identified CMOS. These plans will be monitored till completion. Further, your company monitors performance for all suppliers and vendors through the EcoVadis assessment.

Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders

Our endeavour is to create long-term value creation for all our stakeholders. Your company has been able to build trust with a broad range of stakeholders through a continued focus on quality of product delivery and ethical business conduct. We have developed robust processes for stakeholder engagement to help us in timely identification of stakeholder expectations, conflicts and concerns.

Essential Indicators

1. Describe the processes for identifying key stakeholder groups of the entity.

Any individual or group of individuals or institution/s that enhances the value of your Company's business chain is identified as a critical stakeholder. This *inter alia* includes Employees, Suppliers, Investors, Consumers, Health Care Professionals (HCPs), regulators and community members and organizations. Your Company strives to maintain a strong relationship with all stakeholders and uphold our commitment to fulfil their expectations and requirements.

2. List stakeholder groups identified as key for the entity.

Stakeholder Group	Whether Identified as Vulnerable and Marginalized Group (Yes/No)	Channels of Communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of Engagement	Purpose and Scope of Engagement including Key Topics and Concerns raised during Such Engagement
Patients and Consumers	Yes	Webcasts, Social media pages, Websites, Posters, Standees, Pamphlets, Face to face meetings	Need based	<ul style="list-style-type: none"> Disease awareness programs / Vaccination awareness programs are organized to educate the general public including patients about the signs, symptoms, diagnosis, treatment and prevention options for a disease to foster better patient outcomes through prevention, early diagnosis, and management to minimize or slow disease progression and complications.
Healthcare Professionals (HCPs)/ Healthcare Organisations (HCO)	No	Face to face, Emails, Webcasts, Social media pages, Doctor networking platforms, SMSs, Instant messaging platforms, Congress exhibits etc.	Need based	<ul style="list-style-type: none"> Keep the HCP/HCO abreast with the latest information on product and science, access to product and to gain understanding of the disease and its management To provide avenues for HCPs/ HCOs to discuss and deliberate on latest data, clinical challenges, multidisciplinary expert discussions, new published data intending to help improve treatment outcomes for our patients Disseminate responsible sales and marketing practices including alignment with local laws and applicable industry codes
Investors	No	Annual General Meeting, Analysts' Meet, Detailed Company information made available online	As required	<ul style="list-style-type: none"> Financial performance and business outlook

Stakeholder Group	Whether Identified as Vulnerable and Marginalized Group (Yes/No)	Channels of Communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website), Other	Frequency of Engagement	Purpose and Scope of Engagement including Key Topics and Concerns raised during Such Engagement
Government and Drug Regulators	No	Websites, Emails, Meetings, Industry Forums, Submissions through online Regulatory Agency portals or direct submissions to Regulatory Agency office	As required	<ul style="list-style-type: none"> Policy and Regulatory Matters Grant and maintenance of licences to manufacture and market GSK's products in India Pricing of medicines and other regulatory approvals
Community, NGOs, multilateral organizations	Yes	Partnering with multilateral organisations like the World Health Organization (WHO), NGOs/institutions	As required	<ul style="list-style-type: none"> Enhancing access to medicines Achievement of the UN Sustainable Development Goals and World Health Organization (WHO) targets for specific disease areas Promoting healthcare and education
Suppliers	No	5 step Procurement Processes – Supplier Market Research, RFPs, Bidding, Supplier Relationship management, and contract management	Regularly	<ul style="list-style-type: none"> Business growth and financial stability Sustainable procurement practices Achievement of global sustainability goals and targets
Employees	No	Internal communications, Employee Resource Groups Manager/ employee evaluations and surveys.	Regularly	<ul style="list-style-type: none"> Business outlook and performance Career opportunities and personal development Inclusive and diverse work environment

Leadership Indicators

1. Provide the processes for consultation between stakeholders and the Board on economic, environmental, and social topics or if consultation is delegated, how is feedback from such consultations provided to the Board.

Your company's India Leadership Team (ILT) is responsible for consultation with stakeholders and the Board on economic, environmental and social topics. Regular communication is maintained between ILT members and the Board and your company's stakeholders. Consideration and approval of all operational matters including but not limited to, safety, health and environment policies, product development programmes, decisions with respect to quality of your company's products, services and the environment is overseen and monitored by the ILT. The ILT convenes at least monthly, and more frequently if required. Minutes of each meeting are presented to the Board of Directors.

2. Has stakeholder consultation been used to support the identification and management of environment and social topics? If so, provide details of instances as to how the inputs received from stakeholders?

Central to our business success and financial and reputational growth is garnering regular stakeholder insights and feedback. Administered in full or dipstick, our GSK Culture Survey has been designed to identify and collect employee opinions and concerns on our efforts to provide a conducive working environment. Insights gathered through this survey enable us to take timely action to meet the expectations of our employees and enable them to achieve their true potential. Our Employee Resource Groups also serve as platforms to understand levels of satisfaction amongst our employees and identify any improvement areas with respect to our policies and processes in a timely manner.

We engage with our value chain partners through a five-step procurement process on critical aspects of sustainable procurement activities. Regular engagement with the community and NGOs is also focused on gathering insights on improved ways in which your company can create positive social impact.

3. Details of instances of engagement with, and actions taken to, address the concerns of vulnerable/ marginalized stakeholder groups.

Engagement with vulnerable and marginalised stakeholder groups is undertaken through your company's Corporate Social Responsibility (CSR) activities. Our CSR approach has been designed to encourage empowerment of vulnerable communities and provide them with ample opportunities of growth and development. Core focus areas of our CSR activities include education, nutrition and healthcare.

In order to gauge the impact, your company also undertakes impact assessments of projects. For FY 2023-24, your company has conducted an impact assessment of the Lymphatic Filariasis (LF) Elimination Programme, undertaken with technical support with the World Health Organization (WHO). Assessment findings demonstrate an improvement in the coverage of population across India, especially with services of mass drug administration (MDA). The average coverage of MDA rounds in the districts is 82% as of 2023-24. About 8% of the total endemic districts have cleared pre-TAS (pre-Transmission Assessment Survey), and 41% districts have cleared TAS (Transmission Assessment Survey), as of 2023-24 thus signalling the cessation of MDA rounds.

Principle 5: Businesses should respect and promote human rights

As a multinational organisation with global outreach, we recognize that we have a role to play in upholding human rights and in addressing adverse human rights impacts where we are in a position to influence. We have adopted a strict zero tolerance approach towards violence, harassment, unreasonable, offensive or threatening behaviour of any kind.

Our Code of Conduct outlines the responsibilities of each individual within your company towards the protection of human rights. We conform to all applicable national laws, GSK policies and the expectations set forth in the international bill of human rights.

Your company's Statement on Human Rights can be accessed at [GSK/Human rights statement](#).

Essential Indicators

1. Employees and workers who have been provided training on human rights issues and policy(ies) of the entity.

Your company conducts periodic training related to the code of conduct, ethics, inclusion and diversity, etc. These are mandatory in nature for all our employees.

2. Details of minimum wages paid to employees and workers.

Category	Total (A)	Equal to Minimum Wage		Equal to More than Minimum Wage	
		No. (B)	% (B/A)	No. (C)	% (C/A)
Male Permanent Employees	1,324	0	-	1,324	100%
Female Permanent Employees	251	0	-	251	100%
Total Permanent Employees	1,575	0	-	1,575	100%
Male Permanent Workers	1,451	0	-	1,451	100%
Female Permanent Workers	185	0	-	185	100%
Total Permanent Workers	1636	0	-	1636	100%

3. a. Details of remuneration/ salary/ wages.

Category	Male		Female	
	Number	Median Remuneration/ Salary/ Wages	Number	Median Remuneration/ Salary/ Wages
Board of Directors (BoD)	2	50,664,939	-	-
Key Managerial Personnel (KMP)	8	18,857,719	4	13,378,551
Employees other than BoD and KMP	1314	1,502,508	247	1,771,372
Workers	1451	910,500	185	884,569

b. Gross wages paid to females as % of total wages paid

	FY 2023-24	FY 2022-23
Gross wages paid to females as % of total wages	15.12%	12.60%

4. Do you have a focal point (individual/ committee) responsible for addressing Human Rights impacts or issues caused or contributed to by the business?

Yes. Your company's India Leadership Team is the focal point responsible for addressing all Human Rights impacts or issues.

5. Describe the internal mechanisms in place to redress grievances related to human rights issues.

Any concerns of misconduct, potential unethical and illegal actions, sexual harassment or violation of any Human Rights can be reported by all stakeholders through your company's 'Speak Up' Platform. This platform, managed by independent third-party personnel, provides for a safe and confidential channel to report and redress any grievances with respect to Human Rights. The Speak Up platform can be accessed at <http://www.gsk.com/speakup> on your company's website. Further, your company has also formalised a Whistleblower policy for the reporting of any potential or actual breach of our Code of Conduct.

6. Number of Complaints on the following made by employees and workers.

Child Labour	<ul style="list-style-type: none"> No complaints relating to child labour, forced labour, wages in the current or previous financial year.
Forced Labour	
Wages	
Sexual harassment	<ul style="list-style-type: none"> 1 sexual harassment complaint was filed for FY 2023-24 and 3 sexual harassment complaints filed for FY 2022-23. All complaints were resolved within the prescribed timeline
Discrimination at workplace	<ul style="list-style-type: none"> No complaints were filed in FY 2023-24. 2 complaints have been filed for FY 2022-23, which were closed within the given timeline

7. Complaints filed under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013, in the following format:

	FY 2023-24	FY 2022-23
Total Complaints reported under Sexual Harassment on of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH)	1	3
Complaints on POSH as a % of female employees / workers	0.23%	0.71%
Complaints on POSH upheld	1	3

8. Mechanisms to prevent adverse consequences to the complainant in discrimination and harassment cases.

Enshrined in your company's policy on safeguarding people who report unethical or illegal conduct, retaliation against anyone who reports concerns is strictly prohibited. Any employee who threatens or engages in retaliation or harassment of someone who has reported, or is considering reporting a concern in good faith, is faced with appropriate disciplinary action, in compliance with local labour laws.

9. Do human rights requirements form part of your business agreements and contracts? (Yes/No)

Standard contractual clauses for labour rights which requires self-assessment on issues of child labour, forced labour, safe and healthy workplace, non-discrimination, abusive practices, minimum wages, working hours, and trade unions is included in all business agreements and contracts.

10. Details on Assessments of the year.

Matters	Details
Child labour, Forced/involuntary labour, Sexual harassment, Discrimination at workplace, Labour	No specific assessments were carried out by your company or any statutory body or third parties. However, your company ensures strict internal compliance to all relevant laws and regulations, as applicable
Wages	

11. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from the assessments at Question 9 above.

Since your company is compliant, there was no corrective action suggested by an auditing or inspecting authority for FY 2023-24.

Leadership Indicators

1. Details of a business process being modified/ introduced as a result of addressing human rights grievances/ complaints.

Your Company is a global signatory to the International Labor Organisation (ILO) and is committed to protecting and promoting the human rights of its entire workforce and other stakeholders. We support the right of our workforce for freedom of association and collective bargaining and recognise their internal unions. Your company also has a zero-tolerance approach to child labour and forced labour practices and maintains stringent oversight for the same. Furthermore, your company has strict protocols against any kind of discrimination and makes focused efforts to create a safe and inclusive working environment. Your Company has launched 'Udaan', to support the LGBTQAI+ community and promote the protection of their rights. Your Company is committed to upholding the human rights of all individuals and take prompt action to redress any grievance.

2. Details of the scope and coverage of any Human Rights due diligence conducted.

As part of your company's onboarding process for all third-party vendors, suppliers and contract manufacturers, assessment is undertaken on Human Rights aspects. All contracts entered into by your company with third parties include standard contract clause for labour rights which requires self-assessment on issues of child labour, forced labour, safe and healthy workplace, non-discrimination, abusive practices, minimum wages, working hours, and trade unions.

3. Is the premise/office of the entity accessible to differently abled visitors, as per the requirements of the Rights of Persons with Disabilities Act, 2016?

Yes, your company's corporate office in Worli, Mumbai is accessible to differently abled visitors.

4. Details on assessment of value chain partners.

As part of your company's onboarding process for all third-party vendors, suppliers and contract manufacturers, all risks associated with labour rights and health and safety conditions are assessed. Regular audits are also conducted to track and monitor compliance with all contractual requirements.

For FY 2023-24, four of your company's contract manufacturers have been assessed.

5. Provide details of any corrective actions taken or underway to address significant risks/concerns arising from assessments of Question 4 above.

Since your company is compliant, there was no corrective action suggested by an auditing or inspecting authority for FY 2023-24.

Principle 6: Businesses should respect and make efforts to protect and restore the environment

Your company's approach to business is closely integrated with principles of sustainability. Concerted efforts are regularly made to ensure that our operations do not have a negative impact on the environment in and around our operations. We have also successfully integrated the Environment, Health and Safety (EHS) strategy across our value chain. This has enabled us to comply with necessary applicable environmental laws and mandates during manufacturing and commercial activities.

We continue to make focused efforts for the achievement of the global targets of a net-zero impact on carbon and a net positive impact on nature by 2030. We continue to explore ways in which we can contribute to a greater positive impact on the environment. For instance, vaccines are transported regularly and stored in coolers with the Clearing and CFAs and stockists, instead of passive modes such as thermocol boxes and coolants. This has enabled a continued reduction in your company's carbon footprint.

Essential Indicators

1. Details of total energy consumption (in Joules or multiples) and energy intensity.

(Note: below data under (A), (B), (C) is for Nashik and Corporate Office)

Parameter	Unit	FY 2023-24	FY 2022-23
Renewable Sources			
Total electricity consumption (A)	GJ	4,941	2,293.57
Total fuel consumption (B)	GJ	48,442	47,492.3
Total energy consumption through other sources (C)	GJ	0	0
Total energy consumption (A+B+C)	GJ	53,383	49,785.87
Non-Renewable sources			
Total electricity consumption (C)	GJ	50,067	51,731.85
Total fuel consumption (D)	GJ	9,114	6,923.47
Total energy consumption through other sources (E)	GJ	0	0
Total energy consumption (D+E+F)	GJ	59,181	58,655.32
Total energy consumption (A+B+C+D+E+F)	GJ	1,12,564	1,08,441.19
Energy intensity per rupee of turnover		0.0000033	0.0000033
Energy intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)		0.00007476	0.00007396
Energy intensity in terms of physical output¹³		34.29	38.97

2. Does the entity have any sites / facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India?

Your company does not have any sites/ facilities identified as designated consumers (DCs) under the Performance, Achieve and Trade (PAT) Scheme of the Government of India.

3. Provide details of the following disclosures related to water.

Your company continues to make focused efforts for water conservation. These include increased usage of ETP treated water in cooling towers and process improvements for optimum water usage and reduced wastage. Such initiatives have enabled increased water savings. Your company's Nashik site had set a target to reduce water consumption by 20% by 2023. In 2023, this has already been achieved with the Nashik site reporting a reduction of 22%.

Furthermore, your company will be undertaking focused initiatives to replenish 70,000 m³ of water to four villages around the Godavari basin. In partnership with WaterAid, your company will also be implementing projects to make water accessible for 150,000 women in the community.

¹³ Intensity in terms of physical output has been calculated on the basis of MT of ointments produced for the relevant year. It does not include tablets as this cannot be estimated in MT.

(Note: below data for water withdrawal is for Nashik and Corporate Office)

Parameter	FY 2023-24	FY 2022-23 ¹⁴
Water Withdrawal by Source (in kilolitres)		
Surface Water (Nashik plant)	6,277	5,377
Third party water (Nashik and Corporate Office)	83,077	87,108
Total volume of water withdrawal	89,354	92,458
Total volume of water consumption	81,878	85,126.6
Water intensity per rupee of turnover	0.0000024	0.0000026
Water intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)	0.00005438	0.00005806
Water intensity in terms of physical output ¹⁵	24.94	30.59

4. Provide the following details related to water discharged.

Parameter	FY 2023-24	FY 2022-23
Water Discharge (in kilolitres) by destination and level of treatment		
Third party water (Municipal water supplies) – No treatment	7,476	7,358.4
Total water discharged	7,476	7,358.4

5. Has the entity implemented a mechanism for Zero Liquid Discharge? If yes, provide details of its coverage and implementation.

No, your company has not implemented a mechanism for Zero Liquid Discharge. Treated water is used for purposes such as gardening, cooling towers, boilers after recycling etc.

6. Provide details of air emissions (other than GHG emissions) by the entity.

a. For Nashik plant, your company is within the limit specified by the Maharashtra Pollution Control Board (MPCB).

(Note: Below data is the average of data for the four quarters of respective FY)

Parameter	Unit	FY 2023-24	FY 2022-23
NOx	mg/ m3	14.81	13.85
Sox	mg/ m3	6.7	6.3
Particulate matter (PM)	mg/ m3	31.4	15.17

b. For Corporate Office

Parameter	Unit	FY 2023-24	FY 2022-23
NOx	g/Kw-hr	0.80	0.56
Sox	g/Kw-hr	0.49	0.39
Particulate matter (PM)	g/Kw-hr	0.11	0.11
Carbon Monoxide	g/Kw-hr	0.31	0.28

¹⁴ Your company has included reporting on surface water withdrawal for FY 2022-23. Hence, the total water withdrawal and water consumption and water intensity is being restated

¹⁵ Intensity in terms of physical output has been calculated on the basis of MT of ointments produced for the relevant year. It does not included tablets as this cannot be estimated in MT

7. Provide details of greenhouse gas emissions (Scope 1 and Scope 2 emissions) and its intensity.

(Note: below data for greenhouse gas emissions is for Nashik and Corporate Office)

Parameter	Unit	FY 2023-24	FY 2022-23
Scope 1	Metric tonnes of CO2 equivalent	774.32	486.95
Scope 2	Metric tonnes of CO2 equivalent	9,957.92	10,202.75
Total GHG emissions	Metric tonnes of CO2 equivalent	10,732.24	10,689.71
Total Scope 1 and Scope 2 emissions per rupee of turnover		0.0000003	0.0000003
Total Scope 1 and Scope 2 emissions intensity per rupee of turnover adjusted for Purchasing Power Parity (PPP)		0.00000713	0.00000729
Total Scope 1 and Scope 2 emissions in terms of physical output ¹⁶		3.27	3.84

8. Does the entity have any project related to reducing Greenhouse Gas emissions? If Yes, then provide details.

Yes, your company has undertaken active projects related to reducing greenhouse gas emissions. These include a 1MWp solar power plant that has the potential to provide 15% of the electricity requirement and a 5.1 MWp solar plant, leading to a potential carbon reduction of 163 MT. Additionally, your company has also established a 4,500 KL rainwater harvesting pond. We have also made focused efforts for optimization of chiller operations (19.29 tCO₂e carbon reduction), optimization of HVAC AHUs (11 MT Co₂ reduction), compressed air leakage arresting (energy savings of 20,736 Kwh and CO₂ emission reduction potential of 14.28 tCO₂e) and to reduce refrigerant losses (114 T CO₂ reduction). In FY 2023-24, your company's Nashik plant was awarded the Water Trophy 2023, GSC Sustainability of GSK.

9. Provide details related to waste management by the entity.**a. For Nashik Plant**

Parameter	FY 2023-24	FY 2022-23
Total Waste Generated (in Metric Tonnes)		
Plastic	35.29	32.85
E-waste	0.43	0.74
Bio-medical waste	1.85	1.53
Battery waste	2.07 ¹⁵	1.16
Other Hazardous waste (includes used oil, chemical sludge, off specification products and process residues)	164.96	160.4 ¹⁷
Other Non-Hazardous Waste (includes wood, paper, glass and other organic waste)	1,254.50	1,212.32
Total	1,459.10	1,409
Waste intensity per rupee of turnover	0.000000043	0.000000042
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity	0.00000097	0.00000096
Waste intensity in terms of physical output ¹⁸	0.44	0.51

¹⁶ Intensity in terms of physical output has been calculated on the basis of MT of ointments produced for the relevant year. It does not include tablets as this cannot be estimated in MT.¹⁷ Your company has included briquette ash waste in the reporting for hazardous waste generated and hence the amount of hazardous waste and total generated in FY 2022-23 is being restated.¹⁸ Intensity in terms of physical output has been calculated on the basis of MT of ointments produced for the relevant year. It does not include tablets as this cannot be estimated in MT.

Parameter	FY 2023-24	FY 2022-23
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Recycled	1294.13	1247.07
Reused	24.8	0
Other Recovery Operations	0	0
Total	1,318.93	1,247.07
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Incineration	140.17	161.93
Landfilling	0	0
Other Disposal Operations	0	0
Total	140.17	161.93

b. For Corporate Office

Parameter	FY 2023-24	FY 2022-23
Total Waste Generated (in Metric Tonnes)		
E-waste	0	0
Battery waste	0	0
Non-Hazardous Waste		
Dry Waste	16.08	7
Wet Waste	6.53	22
Gardening Waste	0	11
Total	22.61	40
Waste intensity per rupee of turnover	0.000000001	0.000000001
Waste intensity per rupee of turnover adjusted for Purchasing Power Parity	0.000000002	0.000000003
Waste intensity in terms of physical output ¹⁹	0.01	0.01
For each category of waste generated, total waste recovered through recycling, re-using or other recovery operations (in metric tonnes)		
Recycled	22.61	40
Reused	0	0
Other Recovery Operations	0	0
Total	22.61	40
For each category of waste generated, total waste disposed by nature of disposal method (in metric tonnes)		
Incineration	0	0
Landfilling	0	0
Other Disposal Operations	0	0
Total	0	0

¹⁹ Intensity in terms of physical output has been calculated on the basis of MT of ointments produced for the relevant year. It does not include tablets as this cannot be estimated in MT.

10. Briefly describe the waste management practices adopted in your establishments. Describe the strategy adopted by your company to reduce usage of hazardous and toxic chemicals in your products and processes and the practices adopted to manage such wastes.

Your company collects the waste generated from its own operations. On collection, the waste is segregated and handed over to authorised waste handlers for recycling and incineration, as appropriate. Several waste management practices have also been deployed at our Nashik site to reduce waste from ointments and tablets. Further, a GPS approach is also used wherein the weight of hazardous waste is measured and extracted for waste reduction.

Your company continues to focus on reducing the use of single-use plastic. The Kaizen program at the Nashik site offers employees a platform to discuss and discover innovative solutions to further enhance this commitment.

11. If the entity has operations/offices in/around ecologically sensitive areas (such as national parks, wildlife sanctuaries, biosphere reserves, wetlands, biodiversity hotspots, forests, coastal regulation zones etc.) where environmental approvals/clearances are required.

None of your company's operations are located in and around ecologically sensitive areas. Further, all environmental permits and clearances required by law and the statutes of the Maharashtra Pollution Control Board, and the Central Pollution Control Board are obtained and renewed periodically.

12. Details of environmental impact assessments of projects undertaken by the entity based on applicable laws, in the current financial year:

Your company has not undertaken any environmental impact assessment of projects in FY 2023-24. As per the notification of the Ministry of Environment, Forests and Climate Change in India (MOEFCC), an Environmental Impact Assessment (EIA) is supposed to be carried out for industries which have an adverse impact on the environment. The pharmaceutical sector is not notified as an industry which requires an EIA pre-clearance by the MOEFCC. Additionally, your company's pharmaceutical plant in Nashik does not cause adverse impacts on the regional environment and biodiversity. We ensure that strict compliance is maintained with all applicable laws and regulations across our operation

13. Is the entity compliant with the applicable environmental law/ regulations/ guidelines in India, such as the Water (Prevention and Control of Pollution) Act, Air (Prevention and Control of Pollution) Act, Environment protection act and rules thereunder (Y/N). If not, provide details of all such non-compliances.

Yes, your company is complaint with all applicable environmental laws/regulations/guidelines in India, monitored through a centralised system. Your company has had no major non-compliances for FY 2023-24.

Leadership Indicators

1. Water withdrawal, consumption and discharge in areas of water stress (in kilolitres).

- Name of the area: Ambad, Nashik
- Nature of operations: Manufacturing

Parameter	FY 2023-24	FY 2022-23 ²⁰
Surface Water	6,277	5,377
Third party Water – Municipal Water	72,397	76,596
Total water withdrawal (third party water – municipal water supplies)	78,674	81,973
Total water consumption	78,674 ²¹	81,973 ²²
Water intensity per rupee of turnover	0.0000023	0.0000025

²⁰ Your company has included reporting on surface water withdrawal for Nashik plant from FY 2023-24. Hence the total water consumption, water withdrawal and water intensity for FY 2022-23 is being restated.

²¹ 38,473 KL of water is used for site gardening and recycled water use applications such as cooling towers in FY 2023-24

²² 46,239 KL of water is used for site gardening and recycled water use applications such as cooling towers in FY 2022-23

2. With respect to the ecologically sensitive areas reported at Question 10 of Essential Indicators above, provide details of significant direct & indirect impact of the entity on biodiversity in such areas along-with prevention and remediation activities.

Your company does not have operations in ecologically sensitive areas.

3. If the entity has undertaken any specific initiatives or used innovative technology or solutions to improve resource efficiency or reduce impact due to emissions / effluent discharge / waste generated, please provide details of the same as well as outcome of such initiatives.

Sr. No.	Initiative Undertaken for Calendar Year	Outcome of the initiative
1.	Laminated tube filling line for T-Bact Ointment 5g	The reduction on CO2 emission reduction is quite significant (90%) moving packing material from 5gm T bact Alu to Lami.

4. Does the entity have a business continuity and disaster management plan?

A global business continuity and disaster management assessment is carried out for all functions once in 3 years. Based on the findings, disaster management plans are formulated based on the priority and materiality assessed.

5. Disclose any significant adverse impact to the environment, arising from the value chain of the entity. What mitigation or adaptation measures have been taken by the entity in this regard?

Your company is committed to managing and reducing the environmental impacts of its operations and products across their lifecycle globally. We have obtained all necessary permissions to operate under the pollution control limits set by the pollution control boards and we report on the same periodically. Also, your company follows Good Manufacturing Practices which mitigate some of the risks in this regard. Value chain partners are assessed at the time of onboarding and periodically for compliance with these issues.

6. Percentage of value chain partners (by value of business done with such partners) that were assessed for environmental impacts.

Your company's key contract manufacturers are assessed for environmental impacts once in every three years. For FY 2023-24, four contract manufacturers underwent this assessment. Regular assessment on water risk based on site's current water profile, analysis based on the Aqeduct tool & WWF water risk assessment tool, and CGWA (Central Ground Water Authority) requirements are also undertaken of our key CMOs. Further, in accordance with AMR Industry Alliance Common Manufacturing Framework, your company makes focused efforts to prevent an adverse environmental footprint from the production of antibiotics at the Nashik and third-party contract manufacturers' sites by controlling the release of antibiotics into the environment within the science-driven risk-based discharge limits.

Principle 7: Businesses, when engaging in influencing public and regulatory policy, should do so in a manner that is responsible and transparent

We are committed to advocating for policies that protect the interests of patients, our business and the pharmaceutical sector in India. We undertake active engagement with different industrial, trade and government bodies on sector specific critical issues such as drug pricing and clinical trials. Our code of conduct is a critical guiding document that enables us to maintain our interactions with these associations with transparency and with integrity. As responsible corporate citizen, we do not make any political contributions.

Essential Indicators

1. a. Number of affiliations with trade and industry chambers/ associations: Four
- b. List the top 10 trade and industry chambers/ associations (determined based on the total members of such a body) the entity is a member of/ affiliated to.

Sr. No.	Name of the Trade and Industry Chambers/ Associations	Reach of Trade and Industry Chambers/ Associations (State/National)
1.	Organization of Pharmaceutical Producers of India (OPPI)	National
2.	Federation of Indian Chambers of Commerce and Industry (FICCI)	National
3.	India Business Councils of US (USIBC), US-India Strategic Partnership Forum (USISPF) and UK (UKIBC)	Global
4.	Indian society for clinical research (ISCR)	National
5.	European Federation of Pharmaceutical Industries and Associations (EFPIA) India Regulatory network	Global

2. Provide details of corrective action taken or underway on any issues related to anti-competitive conduct by the entity, based on adverse orders from regulatory authorities.

Your company has not received any order from regulatory authorities on issues related to anti-competitive conduct for FY 2023-24.

Leadership Indicators

1. Details of public policy positions advocated by the entity.

Your company is not involved in matters directly relating to public policy advocacy. However, our regulatory affairs and government affairs teams are actively involved in government advocacy activities by representing GSK's position to trade associations and participating in meetings with regulators and as representatives of trade associations such as OPPI, ISCR, EFPIA India Regulatory network, FICCI, USIBC, USISPF and UKIBC.

Principle 8: Businesses should promote inclusive growth and equitable development

We strongly recognise the role we must play to create positive social impact for society at large. Recognising the need for access to quality and affordable healthcare and education, our CSR programmes have been designed to create ample opportunities of empowerment for all our communities. Such activities enable us to realise our purpose and create long-term positive social impact.

Essential Indicators

1. Details of Social Impact Assessments (SIA) of projects undertaken by the entity based on applicable laws, in the current financial year.

Your company’s plant and operations do not fall under the purview or warrant the need for a Social Impact Assessment (SIA).

2. Provide information on project(s) for which ongoing Rehabilitation and Resettlement (R&R) is being undertaken by your entity.

None of your company’s operations and units have caused displacement to local communities due to which Rehabilitation and Resettlement (R&R) would need to be undertaken.

3. Describe the mechanisms to receive and redress the grievances of the community.

Engagement with local communities is extensively undertaken through your company’s CSR activities. An annual review of CSR action plans and activities is undertaken by the CSR Committee to provide for alignment with local community needs and requirements. Robust mechanisms to maximise outcomes and assess the impact of the CSR projects have also been formalised.

4. Percentage of input material (inputs to total inputs by value) sourced from suppliers.

	FY 2023-24	FY 2022-23
Directly Sourced from MSMEs/Small Producers	6.46%	9.6%
Directly Sourced from within India ²³	74%	72% ²⁴

5. Job creation in smaller towns – Disclose wages paid to persons employed (including employees or workers employed on a permanent or non-permanent / on contract basis) in the following locations, as % of total wage cost.

Not Applicable. Your company’s approach to hiring is location agnostic. Hence wages paid is based on job role and there are no geographical variations.

Leadership Indicators

1. Provide the following information on CSR projects undertaken by your entity in designated aspirational districts as identified by government bodies.

Under the ambit of your company’s GSK Scholars programme, the following aspirational districts have been covered for FY 2023-24:

Sr. No.	State	District	Amount Spent (INR)
1.	Andhra Pradesh	Vishakapatnam	81,159
		Vizianagaram	1,00,000
		YSR (Kadapa)	7,80,140
2.	Assam	Barpeta	18,900
		Goalpara	94,300
3.	Bihar	Jamui	67,850
		Begusarai	60,100

²³ The local purchase amount is the total of invoices received from local vendors during the period.

²⁴ The previous year value of local purchases have been recomputed to be aligned with current year.

Sr. No.	State	District	Amount Spent (INR)
4.	Jharkhand	Giridh	76,504
		West Singhbhum	47,855
		Hazaribag	82,630
		Palamu	1,00,000
5.	Karnataka	Raichur	11,66,233
		Yadagiri	4,83,846
6.	Kerala	Wayanad	96,610
7.	Maharashtra	Nandurbar	90,660
8.	Odisha	Dhenkanal	1,00,000
9.	Rajasthan	Karauli	1,00,000
10.	Tamil Nadu	Ramanathapuram	40,532
11.	Uttar Pradesh	Sonbhadra	1,00,000

2. Do you have a preferential procurement policy for vulnerable/ marginalized suppliers?

No, your company does not have a preferential procurement policy for vulnerable/marginalised suppliers. However, as enshrined in our Code of Conduct, we are committed to working with suppliers who bring value to our business and demonstrates alignment with our internal standards. Further, we also ensure to follow inclusion and diversity in our supply chain by undertaking fair and non-discriminatory practices across our supply chain. Hence, where appropriate, we make focused efforts to onboard and engage with small businesses and/or diverse owned businesses.

3. Details of beneficiaries of CSR Projects.

Sr. No.	CSR Project	No. of persons benefited from CSR Projects	% Of beneficiaries from vulnerable and marginalised groups
1.	Albendazole contribution for supporting mass drug administration under lymphatic filariasis programme	44.5 million albendazole tablets were donated	100% of beneficiaries indicated under our CSR will fall under the vulnerable and marginalised group.
2.	Addressing child nutrition through a holistic approach – Mother and childcare	4,926 households and 5,295 beneficiaries	
3.	Educational Outreach Programme	16,900	
4.	Awareness building on ante-and postnatal care	1,030 households with 875 beneficiaries	
5.	Holistic care for vulnerable underserved girls	192	
6.	Mainstreaming children who are school dropouts by enhancing their grade level competencies	401	
7.	GSK Scholars – Enabling future healthcare professionals	398	
8.	Providing Home away from Home	483	
9.	Providing smart classrooms in schools	11,027	

Principle 9: Businesses should engage with and provide value to their consumers in a responsible manner

Clearly defined by our 'Code of Practice for Promotional and Non-promotional External Interactions' policy, our approach to promotion of our products is patient centric. We are committed to conforming with high levels of ethical, medical, and scientific standards.

Our endeavour remains to keep our customers' needs first and provide them with safe and high-quality products. We strictly comply with internal protocols and Good Manufacturing Practices (GMP) regulations for manufacturing of our products. Aligned to statutory requirements, packaging of all our products provides necessary information about the product and any additional information that is consistent with scientific evidence. Child resistance packaging has also been included in select products of your company.

Essential Indicators

1. Describe the mechanisms in place to receive and respond to consumer complaints and feedback.

We endeavour to identifying and managing product quality complaints, Human Safety Information (HSI) and Adverse Events (AE) reports to help safeguard consumers who take its products or take part in GSK clinical trials. Complaints or feedback concerning possible side-effects of our products can be registered via our website- GSK/Contact/SideEffects. Consumers may also register complaints through your company's toll-free number 1800-2222-03, made available on product packs or raised directly via telephone (+91-22-24959595). We are committed to protecting our patients and regularly report to relevant authorities on any concern with respect to our products.

To provide for a conducive environment within our operation, employees are also encouraged to report any concern to your company's Pharmacovigilance Team within 24 hours of their awareness, which can be done through the Human Safety Information (HSI) / Adverse Events (AE) reporting email - india.pharmacovigilance@gsk.com. Employees also have a responsibility to report product quality complaints to the Quality function through a centralised email ID - locq-india.product-complaints@gsk.com

2. Turnover of products / services as a percentage of turnover from all products/services that carry information about.

Category	As a percentage to total turnover
Environmental and social parameters relevant to the product	Not applicable - There are no specific environmental and social parameters relevant to the product since the products are pharmaceutical products prescribed by physicians.
Safe and responsible usage	100% - Almost all products are prescriptive products. Hence the dosage/usage instruction for these products is generally as directed by the physician. This directive is mentioned on all its prescription-based products. For non-prescription based products such as some ointments, creams, etc., the usage directions are mentioned on packaging along with the products.
Recycling and/or safe disposal	Not applicable - While your company does not specifically mention any such details on its products, it complies with all statutory requirements of the Pollution Control Boards, Extended Producer Responsibility, etc.

3. Number of consumer complaints.

Category	FY 2023-24		FY 2022-23	
	Received During the Year	Pending Resolution at the End of the Year	Received During the Year	Pending Resolution at the End of the Year
Data Privacy	Nil	Nil	Nil	Nil
Cyber Security	Nil	Nil	Nil	Nil
Advertising	Nil	Nil	Nil	Nil
Delivery of Essential Services	Nil	Nil	Nil	Nil
Restrictive Trade Practices	Nil	Nil	Nil	Nil
Unfair Trade Practices	Nil	Nil	Nil	Nil

4. Details of instances of product recalls on account of safety issues.

For FY 2023-24, your company has had no voluntary recalls or forced recalls.

Voluntary recalls are initiated by your company based on any inconsistencies as tracked by the ongoing monitoring of product quality standards and labelling as defined in GSK's Quality Management System and Good Manufacturing Practice (GMP) regulations in India.

There is a detailed mechanism for handling product recalls by your company. The statutory recalls are mandated by the drug regulatory agency in India and are usually related to product quality testing or labelling discrepancies. Your company follows all statutory recall directions even when your company is not in agreement with the regulator's recommendations and subsequently handles the matter through necessary appellate and legal channels.

5. Does the entity have a framework/ policy on cyber security and risks related to data privacy? (Yes/No) If available, provide a web-link of the policy.

Your company has a global policy on cyber security accessible by all employees on your company's intranet. Additionally, your company has identified and defined 9 privacy principles to follow while dealing with Personal Information (PI) at stages of data collection, storage, use, etc. Relevant trainings are also available and provided for all employees to maintain the authenticity of all data. Moreover, an ongoing communication strategy has been adopted to build awareness around management of privacy principles.

6. Provide details of any corrective actions taken or underway on issues relating to advertising, and delivery of essential services; cyber security and data privacy of customers; re-occurrence of instances of product recalls; penalty / action taken by regulatory authorities on safety of products / services.

Since your company is compliant, there was no corrective action suggested by an auditing or inspecting authority for FY 2023-24.

7. Provide the following information relating to data breaches:

1. **Number of data breaches** - Nil
2. **Percentage of data breaches involving personally identifiable information of customers** – Nil
3. **Impact, if any, of the data breaches** - Nil

Your company monitors and resolves all incidences of data breaches through an internal mechanism, the i-Sight tool. For FY 2023-24, there were no data privacy breaches faced by your company.

Leadership Indicators**1. Channels / platforms where information on products and services of the entity can be accessed (provide web link, if available).**

Your company's products are displayed on their website <https://india-pharma.gsk.com/en-in/products/> and specific information has been provided with respect to their names and their active ingredients.

2. Steps taken to inform and educate consumers about safe and responsible usage of products and/or services.

- Your company undertakes various illness/ disease awareness sessions for public awareness of specific illnesses. We also undertake safe and responsible usage awareness sessions with Health Care professionals (HCPs) via webinars and conferences. Over 80+ million touch points were established through webinars and emailers, coupled with the adoption of state-of-the-art technology platforms for virtual detailing such as Veeva Engage.
- The dosage instructions for the prescriptive drugs are directed by the physicians based on the context of the patient. The product information clearly contains directives to be used only under guidance from a medical practitioner. In case of non-prescriptive drugs, the directions for usage are mentioned.
- Product information leaflets for use by registered medical practitioners / hospitals/ laboratories provide information as directed by regulatory authorities. This information includes the generic name, qualitative and quantitative composition, dosage form and strength, clinical particulars (e.g., therapeutic indication, method of administration), contraindications, special warnings and precautions for use, ability to drive and use machines and overdose.

- Your Company has also conducted an antimicrobial resistance (AMR) awareness campaign called 'Exercise Caution with Irrational Combinations' during World Antibiotic Awareness Week in November 2023 to disseminate information about appropriate antibiotic prescribing principles (AAP) aimed at creating 1.5 Mn touchpoints.
- Your company undertakes various awareness campaigns for safe vaccination for children, adults and expecting mothers to protect them from vaccine preventable diseases (VPDs). Through the & Star Protection Campaign, your company aimed to raise awareness about seven vaccines to protect against 14 diseases recommended by the Indian Academy of Pediatrics (IAP) for children aged one to two years.
- Your company also operates a website – MyVaccinationHUB to provide reliable information about vaccination in 12 Indian languages.
- Your company also fosters awareness on child vaccination through influencers, parenting platforms, mom groups and HCPs as key opinion leaders and media channels.

3. Describe the mechanisms in place to inform consumers of any risk of disruption/ discontinuation of essential services.

Your company has established robust internal communication mechanisms in the form of email communications for timely updates to be provided to CFAs for communication to stockists and consumers with respect to any product recalls and/or disruption to services.

4. Does the entity display product information on the product over and above what is mandated as per local laws? (Yes/No/Not Applicable) If yes, provide details in brief.

All information as required by the Drugs and Cosmetics Act & Rules is made available on your company's product packaging. Anticounterfeit features have also been incorporated on the packaging of some of our products. Other product information includes QR code for locally manufactured products, child safety features on some products, information pamphlets for imported products and correct handling for use of some products.